Helping Alabama patients harmed by Dupixent (dupilumab) pursue justice and compensation
If you or a loved one in Alabama developed T-cell lymphoma or another serious cancer after using Dupixent, you may be eligible to file a Dupixent lawsuit.
At Fob James Law Firm, our Birmingham-based mass tort lawyers help clients across Alabama hold the manufacturers (Sanofi & Regeneron Pharmaceuticals) accountable for injuries caused by dangerous drugs.
Our attorneys have years of experience representing victims in pharmaceutical lawsuits, defective drug litigation, and mass tort claims. We currenly represent over 1000 clients in 48 states. We fight to recover full compensation for medical bills, lost income, pain and suffering, and more.
Why Choose Fob James Law Firm for Your Dupixent Lawsuit
When Dupixent (dupilumab) causes severe reactions, you need a legal team that understands the medical science behind your injuries. At Fob James Law Firm, our attorneys partner with board-certified dermatologists, immunologists, and allergy specialists to review your medical records and document the full extent of your Dupixent-related harm.
Why clients trust our Dupixent legal team:
- Comprehensive medical record evaluations by top specialists
- Deep experience in pharmaceutical and mass tort litigation
- Alabama-based team with real federal and state courtroom experience
- Backed by the power and resources of national drug-injury litigation
- Contingency fee representation — pay nothing unless we win
If you were harmed by Dupixent, we have the medical and legal firepower to fight for the compensation you deserve.
Dupixent Lawsuit: Potential Link to Cutaneous T-Cell Lymphoma (CTCL)
Dupixent (dupilumab) is an injectable biologic drug approved by the U.S. Food & Drug Administration (FDA) to treat conditions such as:
- Moderate-to-severe atopic dermatitis (eczema)
- Certain types of asthma
- Chronic rhinosinusitis with nasal polyps
- Eosinophilic esophagitis (EoE)
Emerging evidence shows a serious concern for some individuals with long-standing, severe eczema. Multiple large database studies and case series report significantly higher rates of cutaneous T-cell lymphoma (CTCL) diagnoses after starting Dupixent, often with rapid clinical worsening or progression shortly after initiation.
While Dupixent does not cause lymphoma in every patient, scientific literature suggests it may unmask or accelerate an underlying lymphoproliferative disorder previously hidden by chronic eczema-like symptoms.
Defendants typically argue that Dupixent only reveals pre-existing lymphoma misdiagnosed as refractory eczema. Yet, with strong dermatopathology, clear biologic mechanisms, time-ordered medical records, and evidence of what the manufacturers knew, plaintiffs can build a compelling case for liability — creating a pathway to substantial verdicts or settlements.
If you were diagnosed with T-cell lymphoma after taking Dupixent, contact our Alabama Dupixent lawsuit attorneys for a free case evaluation.
The Risk of T-Cell Lymphoma Is Real
Several important database studies and case series suggest that Dupixent users have a higher risk of developing (or worsening) CTCL after use.
Large Database Studies
- JAMA Dermatology (April 2024): Analyzed 19,612 atopic dermatitis (AD) patients via TriNetX database. Dupixent users were 4.1x more likely to develop CTCL (OR 4.1, 95% CI 2.1-8.2) vs. non-users. Risk persisted after adjustments; most diagnoses >1 year post-treatment.
- Dermatologic Therapy (August 2024): TriNetX study of 1.18M AD patients. Dupixent linked to 4.6x higher relative risk (RR 4.6, 95% CI 2.5-8.6). Highest in patients >60 and within first year.
- Journal of Allergy and Clinical Immunology (January 2025): FAERS and RNA-Seq analysis. Dupixent showed 30x higher CTCL reporting rate vs. other meds. Suggested mechanism: IL-13 increase accelerates malignant T-cells.
Case Series & Reviews
- JAAD Case Reports (2022): 7 patients with severe AD developed/worsened CTCL after Dupixent. Symptoms progressed rapidly (average 7.8 months); biopsies showed unmasking of hidden lymphoma.
- International Journal of Dermatology (2023): Systematic review of 18 cases. 100% had >50% body involvement pre-diagnosis; advanced stages (III/IV) common. Recommended biopsies 3-4 months post-start if no improvement.
- Blood Journal (November 2023): 25 MSK Cancer Center patients. Median time to CTCL diagnosis: 10 months. No survival difference vs. non-Dupixent CTCL cases, but progression often accelerated.
Other Insights and Key Findings
- 2025: The FDA is reviewing post-marketing reports of CTCL in Dupixent users but has not issued a recall.
- Current labeling: Dupixent’s warning label does not specifically mention lymphoma, creating a potential “failure-to-warn” claim.
FDA FAERS (as of January 2026): Nearly 300 lymphoma reports (138 CTCL-specific), prompting ongoing review for label updates. No direct causation is proven, but this is a strong signal of correlation.
Who Can File a Dupixent-Related Lawsuit in Alabama?
You may be eligible to file a Dupixent injury lawsuit in Alabama if you:
- Were prescribed Dupixent for an approved condition (eczema, asthma, nasal polyps, EoE).
- Later developed T-cell lymphoma, such as CTCL, Mycosis Fungoides, or Sézary syndrome.
- Have medical evidence linking Dupixent use to the diagnosis.
- Live in Alabama, or were diagnosed/treated in Alabama, or your prescription use occurred in Alabama.
- File your claim before Alabama’s statute of limitations expires.
At Fob James Law Firm, we provide a free initial evaluation for Alabama clients. We’ll help determine whether you meet the eligibility criteria and will tailor a strategy under Alabama law.
Claims Typically Brought in a Dupixent Lawsuit
Lawsuits related to Dupixent claim that the drug’s manufacturers:
- Failed to adequately warn doctors and patients about the risk of T-cell lymphoma.
- Marketed Dupixent aggressively despite emerging safety signals.
- Neglected to update the warning label to reflect known cancer risks.
As of 2025, there is no nationwide class action or MDL (multidistrict litigation) established for Dupixent cancer claims, but individual lawsuits are being filed and more are expected.
What Compensation Can You Recover in a Dupixent Lawsuit?
Victims in Dupixent lawsuits may recover damages for:
- Medical expenses (past and future)
- Lost wages and loss of earning capacity
- Pain and suffering
- Emotional distress
- Wrongful death damages (for families of deceased victims)
Each case is unique. Our Alabama Dupixent attorneys can evaluate your medical records, timeline, and legal options during a free case review.
Alabama Statute of Limitations for Dupixent Drug Injury Claims
In Alabama, most defective drug or product liability claims must be filed within two years of the date you discovered (or reasonably should have discovered) the injury. Because statute of limitations laws can be complex and fact-specific, you must act quickly. Delays may permanently bar your right to compensation.
Steps to Take if You Used Dupixent
- Stop using Dupixent only under a doctor’s supervision.
- Obtain your full medical records and pathology reports.
- Document all symptoms and side effects, including dates of usage and diagnosis.
- Contact Fob James Law Firm for a free evaluation of your legal options.
- We can help gather the necessary evidence, identify expert witnesses, and file your claim before deadlines expire.
Litigation Updates: Dupixent Lawsuit & Regulatory Timeline
| Date | Event | Significance for Alabama Clients |
|---|---|---|
| June 2018 | Study found that Dupixent use may be linked to increased risk of transient blood eosinophilia. | Early warning of immune system effects; foundational research. |
| April 2024 | A retrospective cohort study reported Dupixent users had ~4.59× higher relative risk of developing CTCL compared to non-users. | Stronger scientific basis for alleging cancer link. |
| Mid-2025 | Firms across the U.S. began filing individual lawsuits alleging CTCL after Dupixent use; as of now no MDL or class action established. | Alabama clients can act now through individual claim. |
| November 2025 | As of November 2025, the FDA has not issued a recall of Dupixent, and the prescribing label does not yet include a cancer-specific warning for CTCL. | Important for causation and “failure to warn” theory. |
Important Notes for Alabama Clients:
- Because the label has not yet carved out a cancer warning, one of the legal theories is that manufacturers should have known and warned earlier.
- The timeline of your diagnosis, prescription use, and when you or your doctor should have discovered the link may affect your claim and statute of limitations.
- Keep detailed records of your Dupixent use (dates, dosage, prescribing physician), treatment of lymphoma/CTCL, and any evidence of delayed diagnosis.
Frequently Asked Questions
Is there a Dupixent recall?
Not yet. As of 2025, the FDA has not recalled Dupixent, but the agency continues to review reports of lymphoma and other serious side effects.
What cancers are linked to Dupixent?
The primary cancer type linked to Dupixent is cutaneous T-cell lymphoma (CTCL). Other reported cases include Mycosis Fungoides and Sézary syndrome.
Can I join a class action or MDL?
Currently, Dupixent lawsuits are being filed individually. If a federal MDL is established, your Alabama lawyer can help transfer your case to that proceeding.
What does it cost to hire a Dupixent lawyer?
Fob James Law Firm works on a contingency fee basis — you pay nothing unless we win your case.
How do I start a Dupixent claim in Alabama?
Call our Birmingham office or fill out our online form. Our team will review your case, explain your rights, and guide you through the next steps.
What compensation is available in a Dupixent lawsuit?
Alabama Dupixent victims may be entitled to compensation for medical expenses, lost wages, pain and suffering, emotional distress, and other damages. In wrongful death cases, family members may also recover additional damages.
Contact an Alabama Dupixent Lawsuit Lawyer Near Me Today
If you or a family member developed cancer or lymphoma after taking Dupixent, don’t wait. Call Fob James Law Firm at 205-407-6009 or complete our online case evaluation form today for a free consultation.
We serve clients throughout Alabama, including Birmingham, Montgomery, Mobile, Huntsville, and Tuscaloosa.
Our Dupixent lawsuit lawyers in Birmingham, AL are ready to fight for your rights and hold drug manufacturers accountable.